Articles tagged "Kidney transplantation"

2017 American Transplant Congress
The Impact of Elevated Doppler Resistive Indices in Renal Transplant Recipients with Delayed Graft Function.
D. Mikhail,¹ E. Chan,² G. Aboalsamh,³ S. Cruise,⁴ S. Aquil,³ M. Mohamed,³ A. Sener,^1,3 P. Luke.^1,3
¹Urology, Western University, London, ON, Canada; ²Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; ³Multi-Organ Transplant Program, Western University, London, ON, Canada; ⁴Family Medicine, Schulich School of Medicine and Dentistry, London, ON, Canada
INTRODUCTION AND OBJECTIVES: Doppler Ultrasonography is often carried out to determine renal allograft perfusion in the early post-operative period. An elevated resistive index (RI) is…
2017 American Transplant Congress
Depressive Symptoms, Physical Frailty, and Kidney Transplant Adverse Outcomes.
J. Konel, F. Warsame, H. Ying, C. Haugen, M. McAdams DeMarco, D. Segev.
Johns Hopkins, Baltimore, MD
Depression is the most prevalent mental health illness in ESRD patients. Physical frailty, a measure of physiologic reserve, is associated with depressive symptoms. They are…
2017 American Transplant Congress
Donor Kidney Volume Predicts One and Three Month eGFR in Live Donor Kidney Transplant Recipients.
D. Al-Adra,¹ M. Lambadaris,² A. Barbas,¹ Y. Li,² N. Goldaracena,¹ O. Famure,² S. Kim,² A. Ghanekar.¹
¹Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada; ²Kidney Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada
IntroductionThere has been increasing interest in non-immunological factors that may impact long-term graft survival after kidney transplantation. It is hypothesized that transplantation of larger nephron…
2017 American Transplant Congress
Willingness of End-Stage Renal Disease Patients (ESRD) without Hepatitis C (HCV) to Accept a HCV+ Kidney.
P. Reese,¹ D. Goldberg,¹ A. Mussell,¹ M. McCauley,¹ D. Sawinski,¹ N. Molina,² R. Tomlin,² S. Doshi,¹ P. Abt,¹ E. Blumberg,¹ C. Thiessen,² S. Kulkarni,² G. Esnaola.²
¹UPENN, Philadelphia, PA; ²Yale, New Haven, CT
Background: New HCV drugs could reduce the risks of donor-derived HCV infection. However, it is unknown if HCV-negative (HCV-) ESRD patients would accept an HCV+…
2017 American Transplant Congress
Two Promoter Polymorphisms in the Genes Encoding for Complement Regulating Proteins CD46 and CD59 in Kidney Donors Are Associated with Biopsy Proven Acute Rejection.
L. Michielsen,¹ A. van Zuilen,¹ T. Kardol-Hoefnagel,² M. Verhaar,¹ H. Otten.²
¹Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, Netherlands; ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
BackgroundComplement regulating proteins, including CD46, CD55 and CD59, protect cells against self-damage. Because of their expression on the donor endothelium, they are hypothesized to be…
2017 American Transplant Congress
Preformed HLA Donor-Specific Antibodies Disappearance After Kidney Transplantation: Significance and Comparison with Persistent DSA.
D. Redondo,¹ M. Pérez-Sáez,¹ M. Mir,¹ J. Gimeno,¹ C. García,² J. Hernández,² J. Yélamos,³ J. Pascual,¹ M. Crespo.¹
¹Nephrology Department, Hospital del Mar, Barcelona, Spain; ²Laboratori de Referència de Catalunya, Barcelona, Spain; ³IMIM, Barcelona, Spain
The presence of donor-specific antibodies (DSA) increase the risk of antibody-mediated rejection (ABMR) and graft failure in kidney transplant recipients (KTR). We aimed to analyze…
2017 American Transplant Congress
Longer Anastomotic Time Leads to Delayed Graft Function.
M. Heer,^1,2 P. Trevillian,^1,2,3 A. Hibberd.^1,2,3
¹Newcastle Transplant Unit, John Hunter Hospital, Newcastle, NSW, Australia; ²Newcastle University, Newcastle, NSW, Australia; ³Hunter Transplant Research Foundation, Hunter Medical Research Institute, Newcastle, NSW, Australia
Background: Delayed graft function (DGF) occurs at variable rates in renal transplant recipients. It can be deleterious to renal allograft in long term. Various factors…
2017 American Transplant Congress
Eculizumab Treatment on GC3 Recurrence on Renal Graft.
G. Jeantet,¹ D. Bertrand,³ A. Lionet,² D. Anglicheau,⁴ V. Fremeaux-Bacchi,⁵ M. Le Quintrec.¹
¹Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; ²Department of Nephrology, Dialysis and Transplantation, Lille, France; ³Department of Nephrology, Dialysis and Renal Transplantation, Rouen, France; ⁴Transplantation Rénale, Necker Hospital, Paris, France; ⁵Immunology, Hopital Européen Georges Pompidou, Paris, France
Clinical C3G recurrence occured in more than 50% after renal transplantation and is the first cause of allograft loss at 5 years post-transplantation. Eculizumab (EC)…
2017 American Transplant Congress
Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation.
J. Lee, E. Liu, M. Aull, S. Kapur.
Weill Cornell Medical Center, New York, NY
Background: Although it is well established that kidney transplant (KT) in the elderly is beneficial and safe, there is limited literature on the appropriate choice…
2017 American Transplant Congress
Prediction of Positive Cytotoxic and Flow Crossmatches for Sensitized Wait List Candidates: Comparison of Luminex MFI, C1q and FcR Binding Assays.
A. Girnita, E. Woodle.
Surgery, University of Cincinnati, Cincinnati
Clinical relevance of HLA antibodies identified in solid phase assays includes their ability to generate a positive crossmatch (XM) test, which often precludes transplantation. The…